The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

The present invention relates to stem cell-derived microvesicles with enhanced efficacy, a use thereof, and a method for enhancing efficacy, and more particularly, to a use of stem cell-derived microvesicles with an enhanced expression level of microRNAs for the prevention or treatment of stroke, and a method for promoting the production of microRNAs of stem cell-derived microvesicles and enhancing efficacy, and a method for promoting the production of stem cell-derived microvesicles and microRNAs within the microvesicles and enhancing the efficacy of stem cells and microvesicles thereof by 3-dimensionally culturing or ischemically stimulating stem cells. Since the method according to the present invention has excellent effects capable of promoting the production of stem cell-derived microvesicles and microRNAs in the microvesicles and capable of enhancing the efficacy of stem cells or microvesicles isolated therefrom, it is possible to obtain stem cell-derived microvesicles containing high levels of materials including therapeutic microRNAs efficiently and in large quantities through this, and thus, the microvesicles are expected to be able to be usefully used in related research fields and future clinical settings.

The invention is directed to a process for preparing a library of saposin lipoprotein particles, wherein the particles comprise membrane components from a cell or an organelle membrane and a lipid binding polypeptide that is a saposin-like protein belonging to the SAPLIP family of lipid interacting proteins or a derivative form thereof, wherein the process comprises the steps of a) providing a mixture of crude membrane vesicles obtained from a cell or an organelle membrane; b) contacting the mixture of step a) with the lipid binding polypeptide in a liquid environment; and c) allowing for self-assembly of the particles. The invention also provides a process for preparing a purified saposin lipoprotein particle comprising the steps of preparing a library according to the process described above and the additional step of f) purifying the saposin lipoprotein particle from the library. In addition, the invention provides a library of saposin lipoprotein particles and saposin lipoprotein particles obtainable according to the processes of the invention. These can be used in medicine, in particular in preventing, treating or lessening the severity of a disease or for use in a diagnostic method, a cosmetic treatment or for use as vaccination formulation or as a tool for drug development, drug screening, drug discovery, antibody development, development of therapeutic biologies, for membrane or membrane protein purification, for membrane protein expression, for membrane and/or membrane protein research, in particular lipidomics and proteomics, preferably for the isolation, identification and/or study of membranes and/or membrane proteins or creation of a lipidome or proteome database.

Described herein are hybrid nanoparticles that are exosomes loaded with one or more nanoparticle dendrimers. Also included are pharmaceutical compositions including the hybrid nanoparticles and methods of making the hybrid nanoparticles. Also described is a method of treating a human subject by administering to the human subject the above-described hybrid nanoparticles.

In an embodiment, an object of the present invention is to provide a therapeutic and/or preventive agent for a fibrosis such as pulmonary fibrosis, an inflammatory disease and/or an aging disease. In an embodiment, the present invention relates to a therapeutic and/or preventive agent for at least one disease of a fibrosis, an inflammatory disease and an aging disease, comprising extracellular vesicle derived from cell of a tissue or a surrounding tissue thereof where disease can occur, in which the cell is differentiated cell, and relates to a pharmaceutical composition containing the therapeutic and/or preventive agent.

An artificial antigen presenting cell system comprising one or more gelated human dendritic cells and a controlled release system capable of releasing one or more cytokines. Also provided herein are methods for producing the gelated human dendritic cells and uses of the artificial antigen presenting cell system for activating immune cells.

Provided herein are recombinant viruses and artificially coated delivery systems, and methods of use.

The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.

A method comprises preparing initial agent molecules and applying the initial agent molecules to microbes for extracellular vesiculation. Microbial vesicles are generated which contain the initial agent molecules by the microbes. The packaged microbial vesicles are then administered to a host organism. By administering the initial agent molecules as a microbial vesicle package, binding proteins for the initial agent molecules may be co-administered, and cells may uptake numerous initial agent molecules concurrently.

Provided herein are methods and pharmaceutical compositions related to microbial extracellular vesicles (mEVs) obtained from Oscillospiraceae bacteria that can be useful as therapeutic agents.